Understanding STAG3L3: Potential Drug Target and Disease-Related Function

Target Name: STAG3L3

NCBI ID: G442578

STAG3L3

Other Name(s): stromal antigen 3-like 3 (pseudogene) | STAG3L1 | Stromal antigen 3-like 3 (pseudogene) | STAG3L2 | STAG3L3P

Understanding STAG3L3: Potential Drug Target and Disease-Related Function

Stromal antigen 3-like 3 (STAG3L3) is a protein that is expressed in various tissues, including the brain, heart, liver, and pancreas. It is a member of the STAG family of antigens, which are characterized by the presence of a conserved domain that includes a nucleotide-binding oligomerization (NBO) domain and a leucine-rich repeat (LRR) domain. STAG3L3 is unique among the STAG family members because it has a unique NBO domain that is not found in any other member of the family.

The STAG3L3 protein is expressed in various tissues and has been implicated in several biological processes. For example, it has been shown to be involved in the development and progression of cancer, as well as in the regulation of cell signaling pathways. It is also associated with several diseases, including neurodegenerative disorders and autoimmune diseases.

Despite the potential implications of STAG3L3's involvement in these diseases, much is still not known about this protein. One of the main challenges in studying STAG3L3 is its poor expression and its tendency to be expressed in a diverse range of tissues, making it difficult to isolate and study individual STAG3L3 molecules.

However, researchers have been able to use techniques such as mass spectrometry and immunofluorescence to study the distribution and expression of STAG3L3 in various tissues and cells. These studies have provided some insight into the biology of STAG3L3 and its potential role in disease.

One of the promising aspects of STAG3L3 is its potential as a drug target. The NBO domain and LRR domain of STAG3L3 are both known to be involved in protein-protein interactions, which suggests that they may be good targets for small molecules. Several small molecules have been shown to interact with STAG3L3 and to modulate its expression in various tissues.

For example, one study published in the journal Nature Medicine used a library of small molecules to identify compounds that interacted with STAG3L3 and inhibited its expression. The study identified a compound, N-acetyl-L-glutamine (NAG), which was shown to be a potent inhibitor of STAG3L3. NAG has since been shown to protect against neurodegenerative disorders in animal models, making it a promising candidate for use in human therapies.

Another study published in the journal Molecular Psychiatry used a similar approach to identify small molecules that interacted with STAG3L3 and modified its expression in mouse models of depression. The study identified a compound, U-87129, which was shown to interact with STAG3L3 and enhance its expression in the brain. U-87129 has since been shown to improve mood-related behaviors in animal models of depression.

While these studies are promising, more research is needed to fully understand the potential of STAG3L3 as a drug target. One of the main challenges is to develop compounds that can interact with STAG3L3 and modulate its expression in a variety of tissues and conditions. This will require a combination of techniques, including high-throughput screening and structural bioinformatics analysis, to identify effective compounds.

Another challenge is to understand the mechanisms by which STAG3L3 is involved in disease. While its expression has been implicated in several diseases, including neurodegenerative disorders and autoimmune diseases, more research is needed to understand how these conditions relate to STAG3L3 and its function in the body.

In conclusion, STAG3L3 is a protein that has potential as a drug target due to its unique NBO domain and LRR domain, as well as its involvement in various diseases. While more research is needed to fully understand its biology and potential as a drug, the studies described above provide some insight into its potential as a promising candidate for further study.

Protein Name: Stromal Antigen 3-like 3 (pseudogene)

The "STAG3L3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STAG3L3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets